Search results
Results From The WOW.Com Content Network
Treatment is reserved for patients with symptomatic or "active" disease. This is principally because: With the possible exception of allogeneic hematopoietic cell transplantation, T-PLL cannot be cured by current treatment options. T-PLL is a heterogeneous disease.
By definition, these prolymphocytes comprise greater than 55 percent of the cells in the blood and bone marrow. The epidemiology, clinical presentation, pathology, diagnosis, and treatment of B-PLL are discussed here.
The epidemiology, clinical presentation, pathology, and diagnosis of T-PLL are discussed here. The treatment and prognosis of T-PLL are presented separately. (See "Treatment of T cell prolymphocytic leukemia" .)
By definition, these prolymphocytes comprise greater than 55 percent of the cells in the blood and bone marrow. The epidemiology, clinical presentation, pathology, diagnosis, and treatment of B-PLL are discussed here.
PURPOSE We conducted a retrospective analysis to evaluate the safety and efficacy of Campath-1H, an anti-CD52 humanized monoclonal antibody, in previously treated T-prolymphocytic leukemia (T-PLL) patients in a compassionate-use program.
The clinical features, pathogenesis, and treatment of RT will be discussed here. Evolution to a component of B cell prolymphocytic leukemia (B-PLL) during the natural history of relapsed CLL/SLL is also common but is not usually included under the rubric of RT.
The epidemiology, clinical presentation, pathologic features, diagnosis, and differential diagnosis of CLL/SLL will be reviewed here. The pathophysiology, molecular biology, cytogenetic abnormalities, staging, and treatment of CLL/SLL are discussed separately.
Treatment of ATL is discussed separately. (See "Treatment and prognosis of adult T cell leukemia-lymphoma".) EPIDEMIOLOGY. ATL is an uncommon lymphoid neoplasm that occurs in patients with human T-lymphotropic virus, type I (HTLV-I) infection. Incidence varies by population according to the prevalence of HTLV-I infection .
The epidemiology, clinical presentation, pathology, and diagnosis of T-PLL are discussed here. The treatment and prognosis of T-PLL are presented separately. (See "Treatment of T cell prolymphocytic leukemia".) EPIDEMIOLOGY. T-PLL is an extremely rare disease, comprising approximately 2 percent of mature lymphocytic leukemias in adults .
The resulting cytopenias have a variety of systemic consequences, including anemia, bleeding, and an increased risk of infection. The clinical features and diagnosis of HCL will be reviewed here; treatment of this disorder is discussed separately. (See "Treatment of hairy cell leukemia" .)